Susanna Bianca N, Susanna Carolina N, Susanna Fernanda N, Mota Rodrigo T, Barbosa Gabriel C S, Lima Vagner L, Susanna Remo
Department of Ophthalmology, ABC Foundation School of Medicine, Santo André.
Department of Ophthalmology, University of Sao Paulo School of Medicine.
J Glaucoma. 2022 Oct 1;31(10):e96-e100. doi: 10.1097/IJG.0000000000002048. Epub 2022 May 6.
We investigate the efficacy of triple-fixed-combination of bimatoprost/brimonidine/timolol once and twice a day, demonstrating higher intraocular pressure reduction with once-a-day use, and discuss possible implications based on previous literature.
The purpose of this study was to compare the efficacy of a fixed combination bimatoprost-timolol-brimonidine (Triplenex) instilled once-daily with twice-daily in primary open angle glaucoma.
A randomized clinical trial at a public eye care institution. Thirty patients with primary open angle glaucoma were followed up for 3 months. The right and left eyes of these patients were randomly assigned to once-daily (10:00 pm ) or twice-daily (10:00 am ; 10:00 pm ) regimens of fixed combination bimatoprost-timolol-brimonidine. Intraocular pressure peaks were obtained with the water drinking test before the introduction of this medication (basal WDT0), 1 month (WDT1), 2 months (WDT2), and 3 months (WDT3) after starting the use of the fixed combination of bimatoprost/timolol/brimonidine (Triplenex). Variation from peak intraocular pressure at WDT3 to peak at WDT0 was compared within groups of 2 versus once-daily regimen.
Sixty eyes of 30 patients (age: 70.67±9.70 y) were included in this study. Baseline clinical characteristics were comparable between groups. The mean reduction in peak intraocular pressure from WDT0 to WDT3 was 6.1±6.1 mm Hg (30.5%) in the eyes receiving 1 drop per day and 4.3±5.7 mm Hg (21.5%) in the eyes receiving 2 drops per day ( P =0.023). Mean reduction in peak intraocular pressure considering all WDT was also higher in the group with once-a-day treatment (5.90±6.03 vs. 4.46±4.28 mm Hg, P =0.006).
Fixed combination of bimatoprost 0.01%, brimonidine tartrate 0.15%, and timolol maleate 0.5% once-a-day is more effective in reducing peak intraocular pressure as measured by the WDT than twice-a-day dosing.
我们研究了比马前列素/溴莫尼定/噻吗洛尔三联固定组合药物每天滴眼一次和两次的疗效，结果表明每日一次用药能更有效地降低眼压，并根据以往文献讨论了可能的影响。
本研究旨在比较原发性开角型青光眼患者每日一次滴眼和每日两次滴眼使用比马前列素-噻吗洛尔-溴莫尼定（三联组合）的疗效。
在一家公共眼科护理机构进行的一项随机临床试验。30例原发性开角型青光眼患者接受了3个月的随访。这些患者的右眼和左眼被随机分配到每日一次（晚上10:00）或每日两次（上午10:00；晚上10:00）使用比马前列素-噻吗洛尔-溴莫尼定固定组合药物的治疗方案。在开始使用比马前列素/噻吗洛尔/溴莫尼定（三联组合）之前（基础饮水试验眼压WDT0）、用药1个月（WDT1）、2个月（WDT2）和3个月（WDT3）后，通过饮水试验测量眼压峰值。比较每日两次用药组和每日一次用药组中WDT3时眼压峰值相对于WDT0时眼压峰值的变化。
本研究纳入了30例患者（年龄：70.67±9.70岁）的60只眼睛。两组患者的基线临床特征具有可比性。每日滴眼一次的眼睛从WDT0到WDT3眼压峰值的平均降低幅度为6.1±6.1 mmHg（30.5%），每日滴眼两次的眼睛为4.3±5.7 mmHg（21.5%）（P = 0.023）。考虑所有饮水试验眼压测量值，每日一次治疗组眼压峰值的平均降低幅度也更高（5.90±6.03 vs. 4.46±4.28 mmHg，P = 0.006）。
与每日滴眼两次相比，0.01%比马前列素、0.15%酒石酸溴莫尼定和0.5%马来酸噻吗洛尔的固定组合药物每日滴眼一次在通过饮水试验测量眼压峰值时，降低眼压的效果更显著。
